Joanna Soroka
Investment Partner
Driven by passion for collaborating with visionary founders and witnessing the inception of interdisciplinary technologies with the potential to transform patient care.
Joanna combines technical expertise in biotechnology with her business acumen in strategy and innovation.
As a Principal at Hitachi Ventures, she oversees healthcare investments spanning techbio, biotech, life sciences, platforms, data, AI, and robotics and automation.
Previously, she was a Manager in biotech and pharma consulting at PwC, where she focused on the intersection of digital technologies, real-world data, and medicine. Before that, she led strategy, R&D, and innovation management in healthcare IT, diagnostics, and precision medicine at the European Business Innovation Center, and later at Konica Minolta’s Global R&D.
Joanna has a strong background in both the scientific and business aspects of healthcare innovation. She holds an M.Sc. in Biology from Jagiellonian University, a PhD in Biochemistry from the Technical University of Munich, and was a Marie Curie Fellow at Cancer Research UK, where she conducted postdoctoral training in genetics and oncology.
Areas of Interest
- AI
- Biotech
- Data
- Life Sciences
- Platforms
- Robotics and Automation
- Techbio
Active Investments
Perspectives
View All
February 14, 2025
Why We Invested
Bioptimus: The GPT of Biology – Unlocking Deep Insights Across Biological Scales
January 14, 2025
Portfolio News
Bioptimus Hits $76M Funding Milestone and Prepares to Launch Groundbreaking Foundation Model for Biology
March 19, 2024
Portfolio News
Cure51 raises a €15M seed round aiming to crack the code on cancer survival
March 13, 2024
Portfolio News
Exclusive: ‘ChatGPT for DNA’: Relation nabs $35M, with Nvidia backing, for osteoporosis work
September 8, 2023
Portfolio News
Scipher Medicine Receives Medicare Coverage for PrismRA® Test in Rheumatoid Arthritis Patients
September 7, 2022
Why We Invested
Why Hitachi Ventures invested in ArsenalBio and their programmable autologous immune cell therapies for solid tumors
ArsenalBio develops programmable CAR-T therapies using genetic circuits, CRISPR, AI, and data analytics for cancer treatment
ArsenalBio develops programmable cell therapies using genetic circuits to enhance CAR-T therapies for solid tumors. By controlling specificity, on-tumor activation, potency, and durability, the company leverages CRISPR, AI, and data analytics to reprogram T cells and identify new drug candidates for improved cancer treatment.
CEO
Ken Drazan
Sectors
Healthcare
Stage
Series C
HQ
California
Deal Team
Wolfgang Seibold
Joanna Soroka
Bioptimus is building a universal multi-scale, multi-modal Foundation Model for Biology to revolutionize biomedicine research.
Bioptimus is building the world’s first universal multi-scale, multi-modal Foundation Model for Biology. By leveraging expertise from Google DeepMind and the unique MOSAIC dataset, Bioptimus aims to uncover intricate relationships across biological systems at unprecedented scales. This groundbreaking approach is poised to drive the next frontier in biomedicine research.
CEO
Jean-Philippe Vert
Sectors
Digital
Healthcare
Stage
Series A
HQ
Paris
Deal Team
Wolfgang Seibold
Joanna Soroka
Marina Du
Cure51 is building the first global database of cancer survivors to uncover new life-saving medicines.
Cure51 is creating the world’s first global, diversified clinical and molecular database of cancer survivors to uncover life-saving medicines. Through a collaborative network, multiomics, and special biology, it aims to identify therapeutic targets for cancer treatment. The company, co-created with oncology centers, focuses on three cancer indications.
CEO
Nicolas Wolikow
Sectors
Healthcare
Stage
Seed
HQ
Paris
Deal Team
Wolfgang Seibold
Joanna Soroka
Marina Du
Proscia’s AI-powered digital pathology platform enhances research, clinical workflows, and collaboration for biopharma and diagnostics.
Proscia’s Digital Pathology Platform, powered by AI applications, enhances efficiency and efficacy in research and clinical workflows. Concentriq connects image data and computational tools, serving biopharma as a system of record for R&D, while delivering efficient tissue analysis for CROs and enabling seamless collaboration for diagnostic labs.
CEO
David West
Sectors
Healthcare
Stage
Series C
HQ
Pennsylvania, USA
Deal Team
Pete Bastien
Joanna Soroka
Relation Therapeutics combines AI, genomic medicine, and Lab-in-the-Loop to build disease maps and discover novel drug targets.
Relation Therapeutics is a drug discovery company focused on genomics, combining advanced ActiveGraph AI models with Lab-in-the-Loop. This integration allows for seamless single-cell analysis at scale, creating rich maps of disease biology to identify novel drug targets. Their approach accelerates drug discovery by linking genomics and AI-driven insights.
CEO
David Roblin
Sectors
Digital
Healthcare
Stage
Seed
HQ
London
Deal Team
Wolfgang Seibold
Joanna Soroka
Marina Du
Scipher Medicine uses transcriptomics and network biology to uncover molecular signatures for autoimmune disease diagnostics and drug discovery.
Scipher Medicine leverages transcriptomics and real-world evidence to build a precision immunology platform for complex diseases. Combining interactome and network biology with proprietary patient transcriptomics data, the platform uncovers unique molecular disease signatures in autoimmune disease patients, advancing diagnostics, drug discovery, and personalized treatment development.
CEO
Reginald Seeto
Sectors
Healthcare
Stage
Series D
HQ
Massachusetts
Deal Team
Wolfgang Seibold
Joanna Soroka
